Catherine Siener

Catherine Siener, PT, MHS is Director of Endpoint Development and Strategy at Ultragenyx Pharmaceutical, where she works in ultra-rare disease drug development. She brings 37 years of experience as a physical therapist, with a career spanning clinical practice, academia, and clinical research. Catherine began her professional career practicing in acute care, cardiopulmonary rehabilitation, and home health. She later joined the faculty at Washington University, where her clinical, research, and teaching focus was in neurology and geriatrics. She transitioned to the Department of Neurology, where she treated adult and pediatric patients with neuromuscular diseases in both clinical and research settings. It was during this time that her involvement in the drug development pathway was established. As a clinical evaluator, Catherine contributed to recent clinical trials that have since resulted in FDA-approved, disease-modifying therapies. Her expertise in administering clinical outcome ass